Investors

Building a Category-Defining
Regenerative Platform

Oral Biolife is a privately held life sciences company advancing a first-in-class piezoelectric regenerative platform for new bone formation.

Current Status

First-in-class piezoelectric regenerative platform

Lead human program: Ambrilux™ Dental Gel (FIH planned 2026)

Commercial veterinary product Veterinary Dental Gel launched with Phibro

Issued U.S. patent through 2040, with EU filings pending

Clear De Novo regulatory pathway supported by robust preclinical data

Capital Raise

Use of Funds

Oral Biolife is raising capital to support:

Human clinical translation of Ambrilux™

Regulatory advancement

Manufacturing scale-up

Platform expansion across additional bone regeneration indications

We partner with long-term investors who understand platform science, clinical translation, and category creation.

For investment inquiries contact:

Gregory Ambra

Chief Executive Officer

Timothy Glennon

Chief Commercial Officer